A new study has identified the FOXJ1 gene as a potential driver of resistance to taxane chemotherapy during treatment for advanced prostate cancer. This research, led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center, offers crucial new insights into why patients with metastatic disease often stop responding to this class of chemotherapy drugs after initially benefiting.
Taxanes remain the only chemotherapy agents with demonstrated survival benefit in advanced prostate cancer, highlighting the urgency of understanding resistance development.
Key Findings from the Study
The study, published February 14 in Nature Communications, suggests that measuring FOXJ1 gene activity in tumors could help predict which patients might develop drug resistance. This could potentially guide doctors to alternative therapies, thereby avoiding unnecessary toxicity from ineffective treatments.
- Dr. Paraskevi Giannakakou, professor of pharmacology in medicine and director of laboratory research, stated that this is a previously unrecognized role for the FOXJ1 transcription factor.
- "It could serve as a potential biomarker," Dr. Giannakakou added.
- The research also indicates the possibility of developing future therapies to block this resistance pathway and restore drug effectiveness.
- Dr. Fang Xie, instructor at Beth Israel Deaconess Medical Center, and Ada Gjyrezi, manager in the Giannakakou lab at Weill Cornell, are recognized as the co-first authors of the study.
Unraveling the Mechanism of Resistance
The Beth Israel Deaconess research team created mouse models of prostate cancer that had become resistant to the taxane docetaxel. Analysis of these tumors showed that expression levels of FOXJ1 and other related genes were significantly higher in resistant tumors than in drug-sensitive ones.
FOXJ1 is primarily known for controlling genes involved in cilia formation. However, researchers discovered an unexpected role for FOXJ1 in regulating microtubules inside prostate cancer cells. Microtubules are dynamic structures essential for cell division and survival. Taxanes function by binding to microtubules, stabilizing them and disrupting their normal dynamics, which ultimately leads to cancer cell death.
When FOXJ1 levels were increased in prostate cancer cells, the cells became less sensitive to docetaxel in both laboratory experiments and patient-derived tumor mouse models. Conversely, reducing FOXJ1 expression made cancer cells more vulnerable to the drug.
Dr. Steven Balk, professor of medicine at Harvard Medical School and oncologist at Beth Israel Deaconess Medical Center, noted, "These findings identify a role for FOXJ1 in controlling microtubule dynamics in cells without cilia and show that tumor cells can exploit this function for taxane resistance."
The team determined that FOXJ1 activity altered microtubule behavior, which reduced docetaxel's ability to bind and stabilize them effectively. They also identified additional genes regulated by FOXJ1 that influence microtubule function, indicating a broader network orchestrated by FOXJ1 that promotes chemotherapy resistance.
Clinical Relevance and Future Implications
Beyond laboratory findings, researchers analyzed tumor samples from clinical studies and found that FOXJ1 gene amplification was more common in patients who had been treated with taxanes.
Data from a large clinical trial also indicated that patients whose tumors had high FOXJ1 levels before treatment experienced poorer outcomes when docetaxel was added to standard hormone therapy.
Dr. Giannakakou stated that "patients who overexpressed FOXJ1 did not benefit as much from taxane therapy."
While further research is needed, the findings suggest that some tumors may already carry high levels of FOXJ1 prior to treatment, making them less responsive to chemotherapy. Additionally, exposure to the drug may cause cancer cells to increase FOXJ1 activity as they evolve resistance.
Dr. Balk expressed optimism that these insights could lead to improvements in taxane-based therapies for prostate cancer and other cancers where taxanes are used.